Company news: Bristol-Myers Squibb and Regeneron

Share this article:
Bristol Myers-Squibb is launching yet another round of layoffs, reported Pharmalot, which said the total will be around 100 employees across departments including field sales, medical support and data analytics specialists. Pharmalot said the layoffs will mostly center around the company's Plainsboro, NJ, locations and is on top of last month's announcement that it was slashing 479 jobs, with a particular emphasis among sales reps.

In the complete opposite direction, Regeneron -- maker of macular degeneration med Eylea -- is expanding its headcount by around 300 new positions, according to the Business Review. The hires will be based in East Greenbush, NY, where it is adding 65,000 square feet, which the Business Review reported will be used for clinical trials, commercialization, and office space. In a second-quarter earnings presentation in July, Regeneron management said the drug's launch was progressing well and that the company raised expectations for sales to reach between $700 and $750 million for the year, compared to initial estimates of between $500 and $550 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.